- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05344599
Evaluación de la prevalencia de la porfiria hepática aguda en el síndrome de taquicardia postural
Estimación de la frecuencia y las características neurohormonales de la porfiria hepática aguda en el síndrome de taquicardia postural
Postural Tachycardia Syndrome (POTS) is the most common autonomic disorder and is estimated to affect 3,000,000 individuals in the United States, with 80-85% of patients being women. The condition is characterized by a rapid increase in heart rate (HR) that occurs on standing, and chronic symptoms of cerebral hypoperfusion leading to lightheadedness, dizziness, and blurred vision.
The acute hepatic porphyrias(AHP)are among the diseases that present with autonomic cardiovascular(tachycardia)and neurovisceral symptoms (abdominal pain) among others; they present with acute exacerbations Given that there is available treatment for AHP that change the natural progression of the disease, study focuses to investigate the occurrence of AHP in POTS and determine the clinical and neuro-hormonal characteristic of the POTS subgroup that will likely benefit from AHP screening.
This study has one visit that involves, answering some questionnaires, coming to the lab for blood work, genetic testing, and some autonomic function tests. About 50 people will take part in this study.
Descripción general del estudio
Estado
Descripción detallada
Postural Tachycardia Syndrome (POTS) affects ~3 million young women in the United States.(1)These patients have a low quality of life because of chronic presyncopal symptoms, and orthostatic tachycardia that occur while standing. POTS can be the initial presentation of an underlying illness. A substantial group of patients with POTS reported that their symptoms started after an acute illness, surgical intervention, substantial weight loss or after ingesting certain medications. These are the same triggers for acute AHP attacks.
Furthermore, the demographic characteristics of AHP overlaps with that of POTS. AHP also affects primarily young women, in their reproductive age. POTS can have a diverse presentation, some patients present with axonal autonomic neuropathy, and severe gastrointestinal symptoms which are co-morbid conditions also present in chronic AHP.
It is within this context that investigators propose to assess the occurrence of AHP in the general POTS population, identify its clinical presentation and neuro-hormonal characteristics.
Rationale and Endpoints:
- To evaluate occurrence of AHPs in POTS patients with autonomic and neurovisceral symptoms referred to a National Referral Center for the treatment of Autonomic Disorder.
- To determine the autonomic and neuro-hormonal characteristics of AHP-POTS patients compared with POTS patients
Enrollment:
This is a cross-sectional study conducted at the Vanderbilt Autonomic Dysfunction Clinic (ADC). Investigators plan to enroll patients with suspicions of POTS who are referred to the ADC for evaluation and diagnosis.
Study visit:
Single study visit.
Participants will be asked to complete an autonomic symptoms assessment questionnaire (COMPASS 31), and quality of life EQ-5D.
The following laboratory analyses will be performed:
Blood: CBC, CMP, Iron studies (Ferritin and iron studies) Urine PBG, ALA and porphyrins in a spot urine sample with results normalized to urine creatinine.
Genetic testing (Acute hepatic porphyria panel) .
Autonomic function test.
Supine and Standing plasma norepinephrine will be obtained for evaluation of neuro-hormonal changes during orthostasis.
Statistical Analyses
This is a pilot study that will estimate the occurrence of AHPs in POTS patients referred to a National Referral Center for the Treatment of Autonomic Disorders. There is no data available on the prevalence of AHPs in POTS. The prevalence of AHP is one in 6,000 in whites. [ref. Hepatol commun 2019 feb 3(2): 193-206] Given that there are overlapping of symptoms between AHP and POTS, expected that AHP would be overrepresented in POTS patients. The plan is to enroll 50 POTS patients in this pilot study.
Data Analysis Plan:
Standard graphing and screening techniques will be used, to detect outliers and to ensure data accuracy. Continuous endpoints will be assessed for normality. If normality is violated, data transformation will be applied or non-parametric analysis methods will be considered. Investigators will provide summary statistics for both continuous and categorical variables by subject groups (POTS and AHP-POTS). All hypotheses will be tested, at the level of α=0.05. SPSS (version 23.0, SPSS, Chicago, IL) will be used and the open-source statistical package R (R Core Team, 2019 for analyses.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Postural Tachycardia Syndrome
Descripción
Inclusion Criteria
- Age 18 - 65 years
- Individuals having an established diagnosis of POTS defined as the presence of presyncopal symptoms for more than 6 months and orthostatic tachycardia (>30 bpm increase in HR within 10 min after assuming upright position)
- The present of one of the following criteria:
3.1 Family history of acute hepatic porphyria 3.2 Unexplained recurrent (more than one), prolonged (>24 hours) episode of severe, diffuse (poorly localized) abdominal pain AND at least TWO of the following:
- Red to brownish urine.
- Blistering skin lesions on sun-exposed areas.
- Peripheral nervous system manifestations occurring around the time of abdominal pain (i.e., motor neuropathy (paresis), sensory neuropathy (numbness, tingling, limb pain).
- Central nervous system manifestations occurring around the time of abdominal pain (i.e. confusion, anxiety, seizures, hallucinations).
- Autonomic nervous system manifestations occurring around the time of abdominal pain (i.e. hyponatremia(Na<lower limit of normal)), tachycardia, hypertension, nausea and vomiting, constipation).
Exclusion Criteria
- Pregnant or breastfeeding women
- type 2 diabetes mellitus
- History of alcohol or drug abuse
- Inability to provide informed consent or comply with protocol
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: CASE_ONLY
- Perspectivas temporales: CROSS_SECTIONAL
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
AHP Case ascertainment in POTS patients
Periodo de tiempo: During the intervention
|
Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome |
During the intervention
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Cyndya Shibao, M.D, Vanderbilt University Medical Center
Publicaciones y enlaces útiles
Publicaciones Generales
- Garland EM, Raj SR, Black BK, Harris PA, Robertson D. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology. 2007 Aug 21;69(8):790-8. doi: 10.1212/01.wnl.0000267663.05398.40.
- Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993 Jan;43(1):132-7. doi: 10.1212/wnl.43.1_part_1.132.
- Raj SR. The Postural Tachycardia Syndrome (POTS): pathophysiology, diagnosis & management. Indian Pacing Electrophysiol J. 2006 Apr 1;6(2):84-99.
- Loavenbruck A, Iturrino J, Singer W, Sletten DM, Low PA, Zinsmeister AR, Bharucha AE. Disturbances of gastrointestinal transit and autonomic functions in postural orthostatic tachycardia syndrome. Neurogastroenterol Motil. 2015 Jan;27(1):92-8. doi: 10.1111/nmo.12480. Epub 2014 Dec 6.
- Robertson D; New Collective Author. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci. 1999 Feb;317(2):75-7. doi: 10.1097/00000441-199902000-00001. No abstract available.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Nervioso
- Enfermedades Genéticas Congénitas
- Enfermedades metabólicas
- Enfermedades del Sistema Digestivo
- Enfermedades del HIGADO
- Enfermedades de la piel
- Enfermedades De La Piel Genéticas
- Disautonomías primarias
- Enfermedades del sistema nervioso autónomo
- Intolerancia ortostática
- Porfirias Hepaticas
- Porfirias
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades Nutricionales y Metabólicas
- Enfermedades de la piel y del tejido conectivo
- Síndrome de taquicardia ortostática postural
- Coproporfiria Hereditaria
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Servicios de salud
- Instalaciones de atención médica Fuerza laboral y servicios
- Servicios de salud preventivos
- Técnicas genéticas
- Servicios genéticos
- Servicios de diagnóstico
- Prueba genética
Otros números de identificación del estudio
- 210724
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .